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The Epstein-Barr virus (EBV)-encoded BARF0 open reading frame gene products are consistently expressed
in EBV-positive Burkitt’s lymphoma (BL) cell lines, nasopharyngeal carcinoma cell lines, and lymphoblastoid
cell lines (LCLs). Here we show that the BARF0 sequence includes an HLA A*0201-restricted cytotoxic T-lymph-
ocyte (CTL) epitope. By using theoretically predicted HLA A2 binding motifs and peptide-loaded antigen pre-
sentation-deficient T2 cells, polyclonal BARF0-specific CD81 CTLs were isolated from four different healthy
EBV-seropositive donors but not from two seronegative donors. These CTL lines recognized the peptide epitope
LLWAARPRL, which was found to be conserved in 33 of 34 virus strains originating from Caucasian, African,
and Asian individuals. The BARF0-specific CTL lines could lyse EBV-negative BL cells stably transfected with
the BARF0 gene but did not kill HLA A2-matched EBV-positive BL cells and LCLs in a standard 51Cr release
assay. Reverse transcriptase PCR analysis demonstrated that these EBV-positive cell lines expressed signifi-
cantly lower levels of BARF0 mRNA than transfected cells. This data indicated that the BARF0 epitope could
be endogenously processed; however, antigen levels in the target cell were a limiting factor for the effective
interaction between BARF0-expressing cells and CTLs. The limited expression of BARF0 antigen in EBV-
infected BL cells and LCLs might contribute to the escape of immune recognition from virus-specific CTLs
present in the host.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
which infects at least 90% of the world’s population. EBV is
the etiological agent of infectious mononucleosis and is asso-
ciated with a variety of lymphoid and epithelial cancers, includ-
ing Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC),
and Hodgkin’s disease. After primary infection, EBV estab-
lishes a lifelong persistent infection which is thought to be con-
trolled primarily by EBV-specific cytotoxic T lymphocytes (CTLs)
(reviewed in reference 27). The oncogenic potential of EBV is
reflected in its ability to efficiently transform human B cells in
vitro. The resulting latently infected lymphoblastoid cell lines
(LCLs) express a restricted set of EBV genes, including those
for six nuclear antigens (EBNA-1 to -6), three latent mem-
brane proteins (LMP-1, LMP-2A, and LMP-2B) (reviewed in
reference 15), and the novel gene products of the BARF0 open
reading frame (ORF) (5). Three types of latency have been
described for lymphoid cell lines and infected tissues (reviewed
in reference 26). The pattern of latent EBV gene expression
present in latently infected LCLs and some BL cell lines is
termed type III and is characterized by the expression of the
full array of latent proteins. In contrast, some BL cell lines as
well as BL biopsies express only EBNA-1 and BARF0, a pat-
tern which is called latency type I. Type II latency represents
an intermediate phenotype. These patterns of latent expres-
sion are also found during primary B-lymphocyte infection in
vivo and in EBV-associated lymphoproliferative disease, em-
phasizing that latent gene expression is likely to be important
in the process of EBV-mediated cell transformation, virus per-
sistence, and lymphomagenesis.
EBV is detected in the malignant epithelial cells of NPC,
which are thought to be derived from clonal expansion of a
single EBV-infected progenitor cell, thereby implying an etio-
logical role for this virus in these carcinomas (25). It was the
cDNA analysis of an NPC sample which subsequently led to
the recent discovery of two C-terminally overlapping proteins
encoded by the BARF0 ORF of EBV. BARF0 RNA and pro-
tein not only were expressed in EBV-infected B lymphocytes
and epithelial cells, but, most importantly, they were also de-
tected in protein extracts of NPC and BL biopsies and in a
latency type I BL cell line (5, 6, 9, 10). Thus, the BARF0
proteins, EBNA-1, and the LMPs are the only viral proteins
consistently expressed in NPC and BL. As EBNA-1 is not rec-
ognized by HLA class I-restricted EBV-specific CTLs (11, 19),
the BARF0-encoded proteins have become prime candidates
for CTL-mediated recognition and killing of NPC and BL
tumors. There is an increasing body of evidence that latent
EBV infection is controlled primarily by HLA class I-restricted
memory CTL responses. These can be reactivated in vitro by
stimulating lymphocytes from EBV-seropositive donors with
HLA-matched target cells presenting HLA class I- and II-re-
stricted epitopes on the cell surface (reviewed in reference 12).
Recently, we published a novel protocol for the identification
of HLA-restricted CTL epitopes which led to the discovery of
epitopes in LMP-1 (13). The protocol takes advantage of the
peptide transporter (TAP)-negative T2 cell line, which is char-
acterized by low HLA class I cell surface expression and im-
paired endogenous peptide presentation (30). HLA expression
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on T2 cells can be stabilized by exogenously delivered synthetic
peptides, and these peptide-coated T2 cells can then be used to
specifically stimulate memory CTLs. Using this approach, we
have isolated CTLs specific for the BARF0 antigen from four
different healthy EBV-seropositive individuals, and these
BARF0-specific CTLs could recognize endogenously pro-
cessed BARF0 protein expressed in a transfected EBV-nega-
tive BL cell line.
MATERIALS AND METHODS
Cell lines. The TAP-negative BxT hybrid cell line 1.74xCEM (referred to as
T2) (30) was used for peptide stabilization assays. The EBV-positive BL cell lines
Eli (29) and MutuI c59 (7) express latency type I EBV genes, and the BL cell line
MutuIII c62 (7) expresses type III latency genes. BJAB cells originate from an
EBV-negative B lymphoma (17). BL30 (18) and DG75 (2) are EBV-negative BL
cell lines expressing a nonactivated, BL group I-like phenotype. LCLs were
established by exogenous transformation of peripheral B cells (23). All cells were
propagated biweekly in RPMI 1640 medium containing 2 mM glutamine, 60 mg
of benzylpenicillin per ml, 100 mg of streptomycin per ml, and 10% fetal calf
serum (growth medium) at 37°C in a 5% CO2 atmosphere.
Synthesis of peptides. Peptides with unblocked C and N termini were synthe-
sized by the Merrifield solid phase method (Chiron Mimotopes, Melbourne,
Australia) on a 1-mg scale, dissolved in 50 ml of dimethyl sulfoxide followed by 600
ml of water, and finally diluted to 200 mg/ml in serum-free RPMI 1640 medium.
HLA stabilization assay. To identify potential HLA A2 binding sites within
BARF0, the computer program HLA Peptide Binding Predictions was employed
as described elsewhere (http://bimas.dcrt.nih.gov/molbio/hla_bind) (24). Pep-
tides containing these predicted motifs were then used in a standard HLA
stabilization assay with T2 cells as described recently (3, 13). Briefly, T2 cells (5 3
105) were incubated with 100 ml of each of the peptides (50 to 100 mg/ml) for 14
to 16 h at 26°C, followed by incubation at 37°C for 2 to 3 h. HLA A2 expression
on the peptide-coated T2 cells was then measured on a FACSscan (Becton
Dickinson, San Jose, Calif.) with an HLA A2-specific monoclonal antibody (MAb)
(MA2.1; American Type Culture Collection) and an anti-mouse immunoglobulin G
fluorescein isothiocyanate-conjugated antibody (Silenus, Victoria, Australia).
Establishment of polyclonal BARF0-specific CTLs and PHA blasts. Peripheral
blood mononuclear cells (PBMC) from whole blood of HLA A*0201-positive
human donors were separated on Ficoll-Paque, and polyclonal BARF0-specific
CTL lines were generated from the PBMC as described recently (13). Briefly,
2 3 106 PBMC were cocultivated with 4 3 104 gamma-irradiated (8,000 rads) T2
cells sensitized with peptide in growth medium for 7 days. The cultures were then
restimulated with peptide-sensitized, gamma-irradiated T2 cells once per week,
fed twice per week with growth medium containing recombinant interleukin-2
(rIL-2) (10 U/ml), and used as polyclonal effectors in a standard 51Cr release
assay after 17 days. For long-term cultivation (up to 7 weeks) in T-cell medium,
rIL-2 (15 U/ml) and 30% MLA-144 cell supernatant (TIB-201; American Type
Culture Collection) were added. T-cell cultures were routinely phenotyped with
a FACSscan and murine MAbs (all from Becton Dickinson) detecting the anti-
gens CD4 (clones SK3 and SK4; anti-human Leu-3a,b–fluorescein isothiocya-
nate), CD8 (clone SK2; anti-human Leu-2b–phycoerythrin), and CD3 (clone
SK7; anti-human Leu-4–peridinin–chlorophyll–protein A).
Phytohemagglutinin (PHA) blasts were prepared by stimulating 5 3 105 PBMC
with PHA (20 mg/ml) (CSL, Melbourne, Australia) in 2 ml of growth medium.
After 3 days, growth medium containing MLA-144 supernatant (30%) and rIL-2
(15 U/ml) was added. The PHA blasts were maintained for up to 6 weeks with
biweekly replacement of rIL-2 and MLA supernatant without the PHA.
Cytotoxicity assay. CTL lines were tested in duplicate for cytotoxicity in a
standard 51Cr release assay (23). Briefly, 106 target cells were incubated with 50
ml of 51Cr (1 mCi/ml of sodium chromate [250 to 500 mCi/mg of Cr]; Amersham,
Sydney, Australia) in a total of 200 ml and, if applicable, with synthetic peptide
(40 to 60 mg/ml) for 90 min at 37°C. Cells were washed twice in growth medium,
thereby removing excess unbound peptide, and resuspended at 105 per ml. Al-
ternatively, in the peptide titration experiment, peptides were added directly to
the resuspended 51Cr-labelled targets and incubated for 1 h at 37°C, and they
remained present throughout the assay. Target cells (100 ml) were combined with
effector cells (100 ml) at different effector/target (E/T) ratios in 96-well round-
bottomed microtiter plates and, after centrifugation, incubated for 5 h at 37°C.
After a further centrifugation, 30 ml of supernatant per well was harvested and
dried onto 96-well solid scintillation microtiter plates before the radioactivity was
counted in a Topcount Microplate scintillation counter (Packard Instrument
Company, Meridan, Conn.). In some experiments, target cells were preincubated
with an anti-HLA class I MAb (W6/32, ATCC HB-95; final dilution of 1/10 of the
ascites fluid) for 1 h at 37°C before CTL addition.
Generation of BARF0 cell transfectants. The BARF0 nucleotide sequence
derived from an NPC tumor xenograft (C15) (5) was cloned into the end-filled
NotI restriction site within the simian virus 40 transcriptional cassette of the
expression vector EBO-pLPP. This vector contains the EBNA-1/oriP replicon of
EBV for episomal replication and the hygromycin resistance gene for eucaryotic
selection (20). Exponentially growing DG75 cells (5 3 106) were washed in growth
medium and transfected in growth medium with 12 mg of DNA of BARF0 expres-
sion vector or EBO-pLPP vector by using a BioRad Gene Pulser (960 mF, 240 V,
0.4-cm-gap electrode, room temperature, 350-ml assay volume). The cells were
then resuspended in 5 ml of growth medium and after 2 days were selected with
600 mg of hygromycin B (Boehringer Mannheim, Castle Hill, Australia) per ml.
Polyclonal transfectants grew out after 2 to 3 weeks and were stably maintained
in hygromycin B-containing growth medium.
RT-PCR analysis. Total RNA was prepared from exponentially growing cells
by using Total RNA Isolation Reagent (Advanced Biotechnologies, Surrey,
United Kingdom). The RNA was then treated with DNase I, which we have re-
cently shown to be important for the complete removal of episome-based DNA
(16). Conditions for the reverse transcriptase PCR (RT-PCR) assay were re-
cently outlined in detail (16). Briefly, the total RNA was reverse transcribed in
the presence of oligo(dT) primers, deoxynucleoside triphosphates, and Super-
Script-II enzyme according to the protocol of the manufacturer (GibcoBRL,
Melbourne, Australia) in a 20-ml assay mixture. For RT-negative controls, the
SuperScript enzyme was omitted. For amplification of a 227-bp cDNA of BARF0
(position 160586 to 160812 of the B95.8 sequence [1]), primers BARF-LLW59
(59-TGTCCAGCGCTCTGGTCG) and BARF-2 (59-CCACGGCAACCCTTCC
AC) were used. To semiquantify BARF0 expression, b2-microglobulin (b2-M)
was also amplified with primers b2-M59 (59-CCCCCACTGAAAAAGATGAG)
and b2-M39 (59-TCACTCAATCCAAATGCGGC), generating a 131-bp cDNA
fragment. This control was used because the b2-M primer pair flanks a large
intron and there are no pseudogenes of b2-M leading to false-positive signals or
competion effects (21). PCR amplification (20-ml mixture) was performed in a
9600 GeneAmp PCR instrument (Perkin-Elmer, Norwalk, Conn.) with 2.5 U of
Taq DNA polymerase (Promega, Madison, Wis.), 2 ml of RT sample, 200 mM
deoxynucleoside triphosphates, 0.5 mM each primer, and 23 cycles for b2-M or
30 cycles for BARF0 amplification, with the following cycle protocol: 5 min of
denaturation at 95°C; 23 or 30 cycles of 1 min at 95°C, 30 s at 60°C, and 1 min
at 72°C; and 5 min of extension at 72°C. The amplified cDNAs were separated
by electrophoresis on 2.5% agarose gels containing ethidium bromide in TAE
buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0). The gel was photographed
under UV light with Polaroid T-55 film, and the relative amount of each DNA
band was quantified by using a Computing Densitometer 300B system (Molec-
ular Dynamics, Sunnyvale, Calif.).
Sequencing of the BARF0 epitopes derived from different EBV isolates.
Genomic DNA was prepared from LCLs and BL cell lines by a salt extraction
method (22). NPC DNA was prepared from biopsies by using a QIAamp tissue
kit (Qiagen, Clifton Hill, Australia). One microgram of DNA was subjected to 30
cycles of DNA PCR amplification with the BARF0 primers BARF-LLW59 and
BARF-2 and the cycle conditions outlined in “RT-PCR analysis” above. The
BARF0 DNA fragment was separated on a 2.5% TAE-agarose gel and purified
by using the QUIEX II gel extraction kit (Qiagen). Approximately 150 ng of each
purified BARF0 fragment was sequenced by using primer BARF-LLW59, the
PRISM Reader DyeDeoxy terminator cycle sequencing kit, and an ABI 377
DNA sequencing system (Applied Biosystems, Foster City, Calif.).
RESULTS
Generation of HLA A2-restricted BARF0-specific polyclonal
CTL lines. In order to identify potential HLA A2-restricted
CTL epitopes within the BARF0 ORF, the 174-amino-acid (aa)
sequence of BARF0 (nucleotide residues 160470 to 160994 of
the B95.8 strain [1]) was analyzed for HLA A*0201 peptide
binding motifs by the method described recently by members
of our laboratory (13). The two sequences RLLLSLQQV and
LLWAARPRL were identified as potential HLA A2 binding
sites. To determine whether these sequences would bind to HLA
A2, two overlapping 20-aa peptides (peptides 130 and 131) which
corresponded to the BARF0 protein sequence and included
the predicted sequences were synthesized and tested for HLA
A2 binding efficiency by using T2 cells and an anti-HLA A2
MAb. Both peptides 130 (PPRARDRALLWAARPRLLLS)
and 131 (WAARPRLLLSLQQVPEPRLA) (predicted se-
quences are underlined) significantly increased the expression of
HLA A2 on T2 cells compared to untreated cells (Fig. 1). Peptide
130 stabilized HLA A2 expression to a similar strength as the
control peptide YLLEMLWRL, which we have recently shown to
be an HLA A2-restricted CTL epitope within LMP-1 (13).
To determine whether those BARF0 peptide sequences in-
cluded CTL epitopes, PBMC from HLA A*0201 EBV-sero-
positive, healthy donors were stimulated with T2 cells coated
with peptide 130 or 131. After 17 days of culture, these poly-
clonal effector cells were used in a standard 51Cr release assay
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against peptide-sensitized PHA blasts from an HLA A2-
matched donor (LL). Representative data from polyclonal
CTL cultures derived from three different donors (NK, LP,
and AH) are illustrated in Fig. 2. All of the cultures stimulated
by T2 cells coated with peptide 130 lysed peptide 130-coated
PHA blasts but not PHA blasts coated with peptide 131 or
untreated targets. In contrast, CTL cultures stimulated with T2
cells coated with peptide 131 did not recognize peptide 131-
coated PHA blasts. This data indicated that peptide 130 but
not peptide 131 included a CTL epitope. Surprisingly, CTLs
from donor LP stimulated with T2 cells coated with peptide
131 showed some recognition of peptide 130-loaded PHA
blasts. This recognition may have been due to the partially
overlapping regions of peptide 131 and 130 sharing parts of the
LLWAARPRL epitope.
In parallel, the potential of another HLA class I-restricted
CTL epitope was investigated by using an HLA B*3501 bind-
ing peptide in the BARF0 sequence. Although the predicted
peptide specifically increased HLA B35 stabilization on T2
cells, stimulation of PBMC from an HLA B35-positive donor
with T2-coated peptide did not generate a significant CTL
response (data not shown). This underlined the specificity of
the HLA A2-restricted BARF0 CTL epitope.
Definition of the minimal BARF0 CTL epitope. To deter-
mine the minimal length of the CTL epitope present within
peptide 130, overlapping peptides (9 to 12 aa long), which in-
cluded the LLWAARPRL sequence, were synthesized. These
peptides were applied to PHA blasts and analyzed in a 51Cr
release assay with an autologous polyclonal CTL line raised
against peptide 130 from donor NK (referred to as NK-130).
At standard peptide concentrations (.40 mg/ml), all of the
BARF0 peptides containing the LLWAARPRL epitope ren-
dered effective killing of the targets (data not shown). In con-
trast, at limiting peptide concentrations, both the 9-mer LLWA
ARPRL and the 10-mer LLWAARPRLL were efficiently rec-
ognized by the NK-130 CTL line, while the 12-mer ALLWA
ARPRLLL and the 11-mer ALLWAARPRLL elicited very
low levels of CTL-mediated cell lysis. However, the peptide
titration showed that the 9-mer LLWAARPRL was the most
active peptide (Fig. 3).
EBV-seropositive, but not -seronegative, donors display a
strong BARF0-specific CTL response. To find out whether a
BARF0-specific CTL response was present in seronegative
individuals, PBMC of an EBV-negative but HLA A*0201-pos-
itive donor (KA) were stimulated with T2 cells sensitized with
BARF0 peptide 130 or LLWAARPRL. For positive controls,
PBMC of the EBV-positive donor NK were processed in par-
allel. After 17 days of culture, these polyclonal effector cells
raised against peptide 130 or LLWAARPRL (referred to as
KA-130, KA-LLW, NK-130, or NK-LLW) were analyzed
against peptide-coated PHA blasts from donor NK in a stan-
dard 51Cr release assay. As illustrated in Fig. 4A, the CTL lines
NK-130 and NK-LLW, both activated from the EBV-positive
donor NK, specifically lysed the autologous NK PHA blasts
sensitized with peptide 130 or LLWAARPRL but not NK
PHA blasts coated with an HLA A2-restricted control peptide
from LMP-1 (YLQQNWWTL) (13) or untreated targets. In
contrast, the two CTL cultures (KA-130 and KA-LLW) origi-
nating from the seronegative donor KA did not significantly
recognize the HLA A2-matched NK PHA blasts coated with
either the BARF0 or the LMP-1 peptides. To confirm that
both donors indeed had the same HLA A2 subtype, the recip-
rocal experiment was performed with KA PHA blasts as tar-
gets (Fig. 4A). Both BARF0-specific CTL lines of the seropos-
itive donor (NK-130 and NK-LLW) strongly reacted with the
BARF0 peptide (130 and LLWAARPRL)-coated KA PHA
FIG. 1. HLA A2 stabilization analysis with T2 cells. T2 cells were either
untreated (no peptide) or incubated with BARF0 peptide (pep.) 130 (PPRAR
DRALLWAARPRLLLS) or 131 (WAARPRLLLSLQQVPEPRLA). For a pos-
itive control (pos. contr.), peptide YLLEMLWRL from LMP-1 was used. HLA
A2 expression on these cells was then analyzed by using a FACSscan and an
HLA A2-specific MAb.
FIG. 2. Specificities of polyclonal BARF0-specific CTL lines. CTL lines de-
rived from PBMC from three seropositive donors (NK, LP, and AH) were tested
after 17 days of culture in a standard 51Cr release assay against HLA A2-matched
PHA blasts (from donor LL) which were either untreated or coated with BARF0
peptide 130 (PPRARDRALLWAARPRLLLS) or 131 (WAARPRLLLSLQQV
PEPRLA). Data from one representative experiment of three is presented. An
E/T ratio of approximately 10:1 was used in the assay. The effectors were des-
ignated according to their donor origin and sensitizing peptide, e.g., NK-130 CTL
indicates BARF0-specific CTLs from donor NK stimulated by peptide 130.
FIG. 3. Titration analysis for the minimal BARF0 epitope. 51Cr-labelled
HLA A2-positive PHA blasts from donor NK were coated with different con-
centrations of overlapping 9-, 10-, 11-, or 12-aa-long peptide (all of which had the
LLWAARPRL sequence) and assayed for recognition by the autologous poly-
clonal NK-130 CTL line (E/T ratio, approximately 15:1). Representative results
from one of two experiments are shown. Conc., Concentration.
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blasts, in contrast to the case for the KA-130 and KA-LLW
CTL cultures originating from the seronegative donor. Al-
though the KA-LLW CTL culture showed some killing of the
BARF0 peptide-coated targets, it was significantly (approxi-
mately threefold) lower than that of the NK CTL lines.
To confirm these results, a second EBV-seronegative HLA
A*0201 donor (RM) was tested in parallel with a fourth sero-
positive donor (JG). The PBMC of both donors were stimu-
lated with T2 cells sensitized with BARF0 peptide LLWAA
RPRL and analyzed in a standard 51Cr release assay after 18
days of culture (Fig. 4B). Clearly, the JG-LLW CTL line (from
the seropositive donor) specifically lysed the LLWAARPRL
peptide-coated HLA-matched RM PHA blasts. In contrast,
the RM-LLW CTL culture, originating from the seronegative
donor, did not recognize the BARF0 peptide-coated autolo-
gous targets.
In addition, a limiting-dillution assay with PBMC from do-
nor KA or NK and T2 cells sensitized with BARF0 peptide 130
or LLWAARPRL was set up and analyzed after 11 days of
culture as described recently (13). With autologous PHA blasts
either coated with the BARF0 peptide targets or not coated,
no BARF0-specific CTLs could be detected in cultures raised
from the seronegative donor KA, in contrast to significant
CTL-induced lysis from the seropositive donor NK. The pre-
cursor frequency of these BARF0-specific CTL clones was
calculated as 1:534,956 to 1:538,750 with a 95% confidence
limit. Although this frequency was very low, it was significant
and in a range similar to that observed with the minimal CTL
epitope YLQQNWWTL of LMP-1 (13) when tested in parallel
with peptide-coated T2 cells against PBMC of donor NK (data
not shown).
To confirm the HLA A2 restriction of the epitope LLWAA
RPRL, an anti-class I antibody inhibition assay was performed
with HLA A2-matched PHA blasts and the polyclonal CTL
lines NK-130 and NK-LLW. Preincubation of LLWAARPRL-
coated PHA blasts from donor LL with an anti-HLA class I
MAb significantly reduced the specific lysis of these targets.
Moreover, fluorescence-activated cell sorter analysis showed
that both the NK-130 and NK-LLW CTL lines were primarily
CD8 positive, with more than 75% of cells expressing both
CD3 and CD8 and only 3 to 5% CD16- and CD56-positive
LAK cells (data not shown). Taken together, this data identi-
fied the minimal BARF0 epitope as the 9-mer LLWAARPRL,
which could reactivate an HLA A2-restricted CTL response in
EBV-seropositive donors.
Characterization of the BARF0 epitope in EBV-infected BL
cells, LCLs, and NPC biopsies. We and others have recently
shown expression of the BARF0 ORF in a broad spectrum of
EBV-infected cells (5, 6, 9, 10). This raised the question of
whether EBV-positive cells could also endogenously process
the LLWAARPRL epitope. A panel of HLA A2-matched BL
cells expressing latency type I EBV genes (Eli and MutuI), a
BL cell line of type III latency (MutuIII), and LCLs (SB, NK,
and LL) were tested as targets in a standard 51Cr release assay
with the BARF0-specific CTL line NK-130. Surprisingly, none
of these targets appeared to be recognized and lysed (Fig. 5).
This lack of CTL recognition of these targets was not due to a
general impairment in their capacity to endogenously process
antigen, since CTLs directed against another HLA A2-re-
stricted epitope of EBV (from LMP-1) effectively lysed the BL
and LCL targets (reference 13 and data not shown). Further-
more, exogenous addition of peptide LLWAARPRL to these
target cells led to significant CTL-mediated lysis, whereas pep-
tide-coated HLA A2-negative target cells (DM LCL and BL30)
were not recognized (Fig. 5). Thus, the lack of CTL recogni-
tion of the EBV-positive cells was not due to impaired HLA
A2 expression of the target cells.
FIG. 4. EBV-seropositive but not -seronegative individuals display a strong
BARF0-specific CTL response. Polyclonal CTL lines (effectors) derived from
PBMC from HLA A2, EBV-seropositive (EBV1) donors NK and JG or from
seronegative (EBV2) donors KA and RM were tested in a standard 51Cr release
assay against HLA A2 PHA blasts as targets. For effector designations, see the
legend to Fig. 2. An E/T ratio of either 16:1 (for NK-130/CTL and KA-130/CTL)
or 13:1 (for NK-LLW/CTL, KA-LLW/CTL, JG-LLW/CTL, and RM-LLW/CTL)
was used. (A) The PHA blasts (from donors NK and KA) were either untreated
or coated with BARF0 peptide 130 (PPRARDRALLWAARPRLLLS) or LLW
AARPRL (LLW). For negative controls, the HLA A2-restricted peptide YLQQ
NWWTL (YLQ) from LMP-1 (13) was used. The effector cells were tested after
17 days of culture. (B) PHA blasts from donor RM were either untreated or
coated with BARF0 peptide LLWAARPRL (LLW). The effector cells were
tested after 18 days of culture.
FIG. 5. EBV-positive BL cells and LCLs poorly present the BARF0 epitope.
LCLs were generated by infection of B lymphocytes with EBV isolate B95.8 (LL
LCL and SBLCL) or QIMR-Wil (NK LCL and DM LCL). The BL BL30 and the
B-cell lymphoma BJAB are EBV-negative cell lines, whereas MutuI BL and Eli
BL are EBV-positive BLs expressing viral latency I genes. MutuIII is an EBV-
positive BL demonstrating a latency type III pattern. All of these cells were used
as targets which were either untreated or incubated with peptide LLWAARPRL
and analyzed in a standard 51Cr release assay against the polyclonal CTL line
NK-130 (E/T ration, 10:1). Data from one representative experiment of three is
shown. The HLA match between targets and effectors is indicated. NT, not tested.
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Another possible explanation for the lack of CTL recogni-
tion of these EBV-positive cell lines could relate to strain
variations in the BARF0 epitope sequence expressed in these
target cells. Therefore, the DNA region of BARF0 encoding
the LLWAARPRL peptide was sequenced, but no sequence
variation in this region was detected in these target cells. More-
over, a sequence analysis of a panel of 34 different virus iso-
lates from three separate geographical areas showed a nearly
perfect (except for one sample) conservation of the LLWAA
RPRL epitope (Table 1).
BARF0-transfected BL cells were killed by CTLs. The level
of expression of the LLWAARPRL determinant in BL cells
and LCLs provides an alternative explanation for the lack of
recognition by CTLs. In order to test this hypothesis, a BL cell
line was stably transfected with a vector overexpressing the
BARF0 ORF. The BARF0 nucleotide sequence, derived from
an NPC tumor xenograft, was cloned into the expression vector
EBO-pLPP. The BARF0 expression vector or EBO-pLPP
alone was introduced into the EBV-negative, HLA A2-positive
BL cell line DG75 by electroporation, and stable cell transfec-
tants were selected. With the NK-130 CTL line as effector cells
at different E/T ratios in a standard 51Cr release assay, the
BARF0-expressing cells were recognized and specifically killed
(Fig. 6A). Preincubation of the BARF0-expressing targets with
an antibody specific for the nonpolymorphic determinants of
HLA class I significantly reduced the specific lysis. Moreover,
the CTL lysis of BARF0-expressing DG75 cells was diminished
in a cold target inhibition assay by peptide 130-coated, unla-
belled HLA A2-positive LCLs (from donor LL) (Fig. 6B).
With different ratios of competitors (cold) to BARF0-express-
ing targets (hot), LL LCLs coated with peptide 130, but not
untreated LL LCLs, reduced the specific lysis of the BARF0-
expressing targets to control levels. These results indicated that
the LLWAARPRL epitope could be endogenously processed
and efficiently presented in transfected cells overexpressing the
viral BARF0 gene.
The level of antigen density on target cells is a critical pa-
rameter for CTL lysis measured in a standard 51Cr release
assay. The significant lysis of the BARF0-transfected DG75
cells compared to the undetectable lysis of EBV-positive cells
suggested that differences in the levels of BARF0 expression in
these targets may explain the poor CTL recognition of LCLs
and BLs. Therefore, the BARF0 expression level was analyzed
by using RT-PCR. A protocol for reproducible amplification of
the cDNA fragments of BARF0 encoding the LLWAARPRL
epitope region and of the constitutively expressed b2-M was
established with nonsaturated PCR cycle numbers. As demon-
strated in Fig. 7A, no BARF0 cDNA could be detected in the
control vector transfectants or in the RT-negative control sam-
ples. In contrast, the RT-PCR samples showed BARF0 cDNA
which was similar in size to the PCR product amplified from
BARF0 DNA. However, EBV-positive BL cells as well as
LCLs demonstrated lower levels of BARF0 cDNA than the
BARF0 transfectants. Quantitation of the BARF0 signal (nor-
malized to b2-M) demonstrated that there was 7- to 17-fold
more BARF0 cDNA present in the DG75-BARF0 cells than in
the EBV-positive BL cells or LCLs (Fig. 7B). In summary, these
results suggested that the level of antigen expression was critical
for the efficient presentation of the LLWAARPRL epitope.
DISCUSSION
The latent persistent infection of EBV is controlled primar-
ily by the HLA class I-restricted memory CTL response, and
many EBV-associated neoplasms express viral antigens that
can act as targets for CTL-mediated killing of these tumor
cells. There is increasing evidence that most of the EBV-as-
sociated malignancies escape this potent virus-specific CTL re-
sponse by restricting viral gene expression (reviewed in refer-
ences 12 and 27). EBV-positive BL biopsies or NPCs express
EBNA-1 and BARF0 or the combination of EBNA-1, LMP-1,
LMP-2A, LMP-2B, and BARF0, respectively (5, 15). As EBNA-
1 does not include HLA class I-restricted CTL epitopes (11,
19) and only a few HLA class I-restricted CTL epitopes are
known to be included in LMP-1 (13), the novel BARF0 protein
might be an important source of CTL epitopes for immuno-
therapeutic treatment of BL and NPC.
Indeed, this report presents, for the first time, evidence that
the EBV-encoded BARF0 protein contains a CTL epitope and
that EBV-positive individuals have an HLA A*0201-restricted
CTL response to the 9-mer epitope LLWAARPRL. Starting
from theoretically predicted HLA class I binding motifs, pep-
tides were synthesized and exogenously loaded onto antigen
presentation-deficient T2 cells. The BARF0 peptide-coated T2
cells strongly activated in vitro polyclonal CTL lines from four
healthy EBV-seropositive donors but not those from two se-
ronegative individuals. The BARF0-specific CTL lines recog-
nized the endogenously presented LLWAARPRL epitope in
transfected BL cells, indicating that this BARF0 CTL epitope
is of biological relevance. The use of peptide-sensitized T2
TABLE 1. Sequence analysis of the HLA A2-restricted BARF0 CTL epitopes present in EBV isolates from different geographical regions
Reference strain or
no. of isolates Epitope sequence
a Virus origin HLA A2frequency (%)b
B95.8 CTC CTC TGG GCC GCC CGG CCT CGC CTT
L L W A A R P R L
13 --- --- --- --- --- --- --- --- --- Caucasianc 46
- - - - - - - - -
1 -G- --- --- --- --- --- --- --- --- Caucasianc
R - - - - - - - -
16 --- --- --- --- --- --- --- --- --- Chinesed 54
- - - - - - - - -
4 --- --- --- --- --- --- --- --- --- Africane 30
- - - - - - - - -
a The DNA and amino acid (boldface) sequences are compared to those of reference strain B95.8 (residues 160644 to 160670) (1). 2, identity.
b From reference 4.
c IARC290B and EBV-QIMR strains derived from LCLs of healthy Australian individuals.
d NPC isolates from Hong Kong.
e BL isolates IARC/BL36, Eli, Mutu, and Ag876.
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cells is a very powerful approach to reactivate memory CTL
responses; however, this method is also known to induce pri-
mary immune responses, as reported recently (32). Indeed,
prolonged cultivation and repeated stimulation of the PBMC
from the seronegative donor KA with peptide-sensitized T2
cells led to CTL cultures which killed BARF0 peptide-coated
PHA blast targets (data not shown). So far, we do not know if
this indicates the induction of a genuine primary immune re-
sponse against the LLWAARPRL epitope or if this was due to
a cross-reactivity in the in vitro cell cultures of the seronegative
donor. However, the significant differences between the sero-
positive and seronegative donors in the time kinetics and rec-
ognition strengths of the stimulated BARF0 CTLs suggested
that BARF0-specific CTLs were reactivated in EBV-positive
donors from a memory response.
The HLA A2-restricted BARF0 epitope sequence was found
to be conserved in 33 of 34 virus strains originating from Cauca-
sian, African, and Asian individuals. Moreover, the HLA A2
allele has a high frequency in virtually all human populations
(Table 1). This epitope therefore has the potential to be used
in a CTL-based vaccine designed to control EBV-associated
tumors such as Hodgkin’s disease and NPC. In contrast, this
potential is limited in the case of BLs, as these tumors cannot
endogenously process antigens due to downregulated HLA
class I and TAP expression (28). In addition, BARF0-specific
CTLs were unable to lyse EBV-positive BL cell lines, in con-
trast to peptide LLWAARPRL-loaded target cells and
BARF0-transfected BL cells, all of which were killed. The en-
couraging observation that the BARF0-transfected cells could
endogenously process the LLWAARPRL epitope implies that
it was not an intrinsic BARF0 structure (as seen in the case of
EBNA-1, in which antigen processing is prevented by internal
repeats [19]) which inhibited HLA class I-restricted BARF0-
specific CTL lysis of EBV-positive cells. Rather, this suggested
that the amount of BARF0 protein present in the target cell
might be important. Indeed, the RT-PCR data demonstrated
lower levels of BARF0 mRNA expression in EBV-infected
cells than in the BARF0 transfectants. Two recent papers re-
ported the failure of HLA class I-restricted CTLs raised against
EBNA antigens to lyse autologous EBV-infected cells (8, 31).
Although these LCLs presented enough antigen to stimulate
the outgrowth of CTL lines in vitro, both groups demonstrated
that either superinfection with recombinant vaccinia virus en-
coding the appropriate target gene or incubation with the
peptide epitope was necessary to detect lysis of the LCLs in a
standard 51Cr release assay. As this assay is insensitive if fewer
than 10 to 20% of the target cells express the antigen, the
authors postulated that the amount of antigen presented on
the EBV-positive cells may be heterogenous within the popu-
lation of LCLs or BL cells. Since antigen density on the target
cell seems to be a critical factor for the avidity of interaction
between target cells and effector CTLs, it will be necessary to
explore possible ways to increase BARF0 gene expression in
EBV-positive BL cells and LCLs. It is tempting to speculate
that the suboptimal expression of BARF0 antigen in these
FIG. 6. BARF0-transfected BL cells present the LLWAARPRL epitope. (A)
The BL cell line DG75 (EBV negative, HLA A2 positive) was stably transfected
with either a control vector (DG75-EBO) or a BARF0 expression vector (DG75-
BARF0). These targets were analyzed in a standard 51Cr release assay with the
CTL line NK-130 at different E/T ratios. DG75-BARF0 cells were additionally
preincubated with an anti-HLA class I-specific antibody before the addition of
effector cells. (B) 51Cr-labelled DG75-BARF0 cells were subjected to a cold
target inhibition assay with either untreated or peptide 130-coated LL LCLs
(competitor) at different hot/cold target ratios. CTL lysis was induced by the
effector NK-130 CTL bulk culture at an E/T ratio of 10:1.
FIG. 7. RT-PCR of BARF0 expression. (A) Total RNA was reverse tran-
scribed from three EBV-positive LCLs (LL, NK, and SB), two BL cell lines of
type I viral latency (Eli and MutuI), a BL cell line of type III viral latency
(MutuIII), the EBV-negative DG75 cells expressing the BARF0 gene (DG75-
BARF0), or the vector control (DG75-EBO). For RT-negative controls, the RT
enzyme was omitted (cont.2). Both a 131-bp fragment of b2-M and a 227-bp
fragment of BARF0 were PCR amplified from the first-strand cDNAs and the
BARF0 gene DNA (cont.1). These were separated and visualized by electro-
phoresis on an ethidium bromide-containing agarose gel. Data from one repre-
sentative experiment of three is shown. (B) The RT-PCR fragments obtained
from each of the cell lines were quantified, and the BARF0 signals were stan-
dardized against b2-M.
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EBV-infected cells might contribute to the escape of immune
recognition from virus-specific CTLs present in the host.
On the other hand, very high levels of BARF0 RNA and
protein expression have been observed in NPC (5, 6, 9), sug-
gesting that BARF0-specific CTLs might be of immunothera-
putic value for the treatment of this malignancy. Moreover,
NPC cells not only express TAP and HLA proteins, both of
which are limiting factors in antigen presentation, but also dis-
play normal endogenous processing function and are efficiently
recognized by virus-specific CTLs in vitro (14). It is important
to mention here that our limiting-dilution assay data indicated
that the CTL response to the BARF0 epitope constituted a
minor component of the virus-specific CTL response in EBV-
seropositive individuals. Nevertheless, the continuous presence
of this CTL memory response implies constant exposure to
endogenously processed BARF0 antigen. This could be occur-
ring during the persistent stage of EBV infection, when the
EBV latency proteins are expressed and presented to the im-
mune system. Additionally, as the levels of BARF0 protein
were shown to increase after induction of EBV viral replication
(5), the low but continuous lytic cycle of EBV in healthy
asymptomatic individuals could aid in the presentation of
BARF0 antigen. If the high level of BARF0 expression in NPC
cells renders them susceptible to lysis by BARF0-specific
CTLs, it may be possible to amplify this component of the
virus-specific CTL response by vaccination with the relevant
peptide or to adoptively transfer BARF0-specific CTLs to con-
trol this common malignancy.
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